Under construction – not a live service
Sign in
Taking people in MexicoNo phase

Studies lung scarring linked to rheumatic diseases in Mexican patients

Observes lung scarring linked to rheumatic diseases in adults in Mexico.

Plain-language title generated from the registry record
Registry title: Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)

Key facts

Where
Mexico City, MexicoSee the site

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a rheumatic or connective tissue disease who also have interstitial lung disease, confirmed by a high-resolution CT scan. It is a non-interventional study in Mexico.

Age
Over 18 years old.
Sex
Men and women can join.
Disease stage
Interstitial lung disease, diagnosed clinically and by a high-resolution CT scan with an interstitial pattern. It must come with rheumatoid arthritis, a connective tissue disease, spondyloarthritis or sarcoidosis.

Main reasons for not taking part

  • Biopsy showing usual interstitial pneumonitis linked to a cause other than connective tissue disease
  • Pneumonitis after chemotherapy or radiotherapy
  • Medical records without a full diagnosis of interstitial lung disease

Read by machine on 12 November 2026.

Where in Mexico

  • Colegio Mexicano de ReumatologiaMexico City, MexicoContact: Boehringer IngelheimTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Boehringer Ingelheim
Trial code
NCT05819385
Record updated
7 May 2026
Original description
This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progression, exacerbations, and mortality in patients with ILD associated to CTD.Read full original descriptionShow less

Ambispective, Non-Interventional Study to Evaluate the Epidemiology of Interstitial Lung Diseases (ILDs) Associated to Rheumatic Diseases (Rheumatoid Arthritis, Connective Tissue Diseases, Spondylarthritis and Sarcoidosis) and the Progression Risk Factors in the Mexican Population

This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progression, exacerbations, and mortality in patients with ILD associated to CTD.

Inclusion: For newly data collection:; Male and female Patients; Patients over 18 years old; Patient who gives his/her signed informed consent to be able to use information about their condition; Patient who has the diagnosis of: rheumatoid arthritis, connective tissue disease (CTD) (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; systemic lupus erythematosus; primary Sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) Spondyloarthritis (SpA) or sarcoidosis, (accordingly with the updated clinical criteria for each pathology); Patient with any interstitial lung diseases (ILD) diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist); For existing data collection:; Medical Records from patients with whom contact was permanently lost for any reason since 2012 till the study start date; Medical Records from male and female Patients; Medical Records from patients over 18 years old; Medical Records of patients that have at least: patient initials, date of birth, gender, date of diagnosis, full diagnosis of:; Patient who has the diagnosis of: rheumatoid arthritis, CTD (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; Systemic lupus erythematosus; primary Sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) SpA or Sarcoidosis, (accordingly with the updated clinical criteria for each pathology); Patient with any ILD diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist).

Exclusion: Patient with a biopsy definition of usual interstitial pneumonitis, related to any other non-CTD; Patient with post-chemotherapy or post-radiotherapy pneumonitis; Medical Records of patients without full diagnostic of ILD (clinically and by biopsy or high-resolution computed tomography).

ClinicalTrials.gov NCT05819385